Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.
about
Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophreniaResource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE).The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data.Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium.Is the PANSS used correctly? a systematic review.Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study resultsSchizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysisThe role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America.Interrelations between psychiatric symptoms and drug-induced movement disorder.Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases.Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparisonRisperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada.Deltoid injections of risperidone long-acting injectable in patients with schizophreniaLong-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia.Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons.A review of pharmacologic strategies for switching to atypical antipsychoticsEnhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?Psychiatrists' awareness of adherence to antipsychotic medication in patients with schizophrenia: results from a survey conducted across Europe, the Middle East, and Africa.Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics.Risperidone long-acting injection: a review of its long term safety and efficacy.Use of risperidone long-acting injectable in a rural border community clinic in southern californiaProgress in compliance research and intervention: a commentary.A New Psychosocial Tool for Gaining Patient Understanding and Acceptance of Long-acting Injectable Antipsychotic Therapy.Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review.Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic.A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada.Risperidone long-acting injection in the treatment of schizophrenia spectrum illnesses: A retrospective chart review of 19 patients in the Vancouver Community Mental Health Organization (Vancouver, Canada)Evaluating appropriateness of prescribing of long-acting risperidone for injection in acute care settings.The Use of Long-Acting Injectable Antipsychotics in Schizophrenia.Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study.Long-acting risperidone in the treatment of schizophrenia: an evidence-based approach.IVIVC from Long Acting Olanzapine Microspheres.Development of Risperidone PLGA Microspheres.Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection.Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval.
P2860
Q24815361-5224A86D-D5C5-4F9B-9918-53CB7D458CEBQ31038656-B946B3F8-4B67-4C10-8200-91756F743B7AQ31143463-8A81F49F-5EB0-47E9-BADB-5C6BE60E1880Q33862078-5874275C-3156-4C50-B5EB-0049DA9DB2A0Q33964357-3020A68B-73CF-4D6B-82B4-6FF89E180363Q34048194-02845315-ADA9-4C1B-B38B-3257EBEB27F8Q34398243-798C9E35-0D46-4DFF-A04F-A64B43448D9EQ34418847-B543AB0C-C393-4AC3-87D9-29FE0555C987Q34560335-8FEA7911-69D7-446A-AAED-83FE43282A75Q34573844-409F0524-25BD-4770-9646-A5E2AC36DD80Q34693244-97F1D561-F43A-4A30-AC7D-7C5875C16330Q34720828-6BE5BDBA-8B72-45D5-89B4-B407F45AD54EQ34746791-B6BEEDD8-3A41-40D2-BEF5-27825B49DC1BQ35119881-10BC81A2-11DD-4363-9A67-9EC5C8BE6C53Q35143555-3B108E08-DD4C-49FE-AE3A-A5331D784EB6Q35971060-3EFD3E3D-4A16-4879-87A4-6F008020F18AQ36199687-23E9FE2F-7D19-451A-88FD-59946A9B81C7Q36211694-CE5EB345-722F-4730-8FFB-818269A52BA1Q36587739-6A560F26-2B85-40A8-BDD9-F10343BD1ACBQ36672952-9B48E302-1B44-455D-814D-42D85051DF04Q37062563-BDBFFF45-7049-43E0-92D8-D400337A32C8Q37225867-884DB944-A212-4C67-BA9A-BEE587475252Q37236153-18C2CAC1-650B-4BB1-9132-7C755C025A75Q37272606-73E3ACE9-C2B1-4656-95B1-B86803137EAAQ37328709-88F039CB-0B13-4BC5-9506-9180AD9F17A1Q37418931-4CA07721-FAE7-4EFF-AAD9-CC19FF514D35Q37501165-A2E428E6-5F1E-4425-875B-E43570B8DF73Q37616971-872A31AC-A3B8-48BE-94DE-B42A3B2875BEQ37672702-3DDF09B6-42AD-4E06-AB9A-CB72E3DDF897Q38000246-DB74B4F2-EAB6-4451-8ACD-3DD3EE50F466Q38744570-5924CF22-DFD7-4CED-AD3D-DABAD7ECCEFEQ40765718-35B94D0B-D979-40FA-A719-C3A9600BECE1Q41248610-D0C4179E-B24D-4C5F-AC7C-91ACBFF755D8Q41937906-FED972E7-E583-4CE5-985C-60B631764871Q41962765-852CEE1F-7300-4A56-B51C-0791E4DE0D2CQ42252223-C18361F2-1577-4CC5-9650-A5BB7EC20B2AQ42610530-CDB58F25-5A24-4F3E-9269-D764D26638E8
P2860
Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Treatment of schizophrenia wit ...... cond-generation antipsychotic.
@en
Treatment of schizophrenia wit ...... cond-generation antipsychotic.
@nl
type
label
Treatment of schizophrenia wit ...... cond-generation antipsychotic.
@en
Treatment of schizophrenia wit ...... cond-generation antipsychotic.
@nl
prefLabel
Treatment of schizophrenia wit ...... cond-generation antipsychotic.
@en
Treatment of schizophrenia wit ...... cond-generation antipsychotic.
@nl
P2093
P1476
Treatment of schizophrenia wit ...... cond-generation antipsychotic.
@en
P2093
Keith Karcher
Mariëlle Eerdekens
Ola Gefvert
Stephen Martin
W Wolfgang Fleischhacker
Wlodzimierz Chrzanowski
P304
P577
2003-10-01T00:00:00Z